Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The ABNL-MARRO 001 Study
NCT04061421Phase 2Recruiting
- Start
- Nov 2021
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of inqovi, itacitinib and ruxolitinib in myelodysplastic/myeloproliferative neoplasms (MDS/MPN) (2 arms). Primary endpoints: Determination of dose at 28 days and Overall Response Rate at 2 years. Started Nov 2021; status: recruiting.
02
Drugs
03
Conditions
myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
Beyond the preview
Go deeper on NCT04061421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04061421.